M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Connecting Black Families in Houston, Texas to Hereditary Cancer Genetic Counseling, Genetic Testing, and Cascade Testing by Using a Simple Genetic Risk Screening Tool and Telegenetics

Not Applicable

Recruiting

Conditions: Breast Cancer
Colorectal Cancer

Interventions: Behavioral: Screening Form
Behavioral: Genetic Testing and Counseling

First Posted Date: 2023-01-23

Last Posted Date: 2024-08-27

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 1000

Registration Number: NCT05694559

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Perceptions of Hospital Care At Home for Patients with Cancer: a Qualitative Study of Cancer Providers, Patients and Caregivers.

Recruiting

Conditions: Cancer

Interventions: Behavioral: Focus Group
Behavioral: Interview

First Posted Date: 2023-01-23

Last Posted Date: 2025-01-10

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 20

Registration Number: NCT05694650

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma

Phase 1

Recruiting

Conditions: Lymphoma

Interventions: Drug: Rituximab
Drug: Lenalidomide
Drug: Valemetostat

First Posted Date: 2023-01-13

Last Posted Date: 2024-12-13

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 60

Registration Number: NCT05683171

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Cultural Tailoring and Pilot Testing of an Inpatient Yoga Therapy Program for Cancer Patients Undergoing Hematopoietic Stem Cell Transplantation in India, Tanzania, and the United States

Not Applicable

Recruiting

Conditions: Hematopoietic Stem Cell Transplantation
Cancer

Interventions: Behavioral: Yoga Sessions
Behavioral: Questionnaries
Behavioral: Interviews

First Posted Date: 2023-01-11

Last Posted Date: 2024-08-22

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 60

Registration Number: NCT05681026

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients With Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC).

Phase 2

Recruiting

Conditions: Squamous Cell Carcinoma
Oral Cavity Squamous Cell Carcinoma

Interventions: Drug: Tiragolumab
Drug: Atezolizumab
Behavioral: Standard of Care
Behavioral: Questionnaires
Radiation: Cisplatin
Radiation: Carboplatin

First Posted Date: 2023-01-11

Last Posted Date: 2025-01-10

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 29

Registration Number: NCT05681039

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Feasibility Study: IGNITE-TX (Identifying Individuals for Genetic Testing & Treatment) Intervention

Not Applicable

Recruiting

Conditions: Hereditary Breast and Ovarian Cancer Syndrome
Gynecologic Cancer
Breast Cancer
Colon Cancer
Endometrial Cancer
Uterus Cancer
Ovary Cancer
Lynch Syndrome
Pancreatic Cancer

Interventions: Behavioral: Free genetic testing and counseling group
Behavioral: IGNITE-TX Group
Behavioral: IGNITE-TX and free genetic testing and counseling group

First Posted Date: 2023-01-10

Last Posted Date: 2025-01-08

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 240

Registration Number: NCT05677048

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Feasibility and Clinical Utility of Cell-free DNA (cfDNA) in Identifying Actionable Alterations and Minimal Residual Disease for Lymphoma Patients Across Community Centers in Texas

Not Applicable

Recruiting

Conditions: Lymphoma

Interventions: Diagnostic Test: cell-free DNA

First Posted Date: 2023-01-09

Last Posted Date: 2024-11-13

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 517

Registration Number: NCT05676450

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Cancer Therapy and Research Center at The UT Health Science Center at San Antonio, San Antonio, Texas, United States

A Phase II Study of Neoadjuvant Sacituzumab Govitecan and Pembrolizumab Therapy for Immunochemotherapy-resistant Early-stage Triple-negative Breast Cancer (TNBC)

Phase 2

Recruiting

Conditions: Breast Cancer

Interventions: Drug: Sacituzumab Govitecan
Drug: Pembrolizumab

First Posted Date: 2023-01-09

Last Posted Date: 2024-12-16

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 25

Registration Number: NCT05675579

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB)

Phase 2

Recruiting

Conditions: Brain Metastases
Metastatic Solid Tumor

Interventions: Drug: Trastuzumab emtansine
Drug: Tucatinib

First Posted Date: 2023-01-06

Last Posted Date: 2024-02-29

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 30

Registration Number: NCT05673928

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

3-5 FrAction Stereotactic Body Radiation Therapy for Palliation of Head and Neck Squamous Cell Carcinoma: the FAST Phase II Randomized Trial

Phase 2

Recruiting

Conditions: Head and Neck Squamous Cell Carcinoma

Interventions: Radiation: Traditional Palliation
Radiation: Stereotactic body radiotherapy

First Posted Date: 2023-01-06

Last Posted Date: 2025-01-09

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 108

Registration Number: NCT05674396

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy